Connection

GEORGE JACKSON to Humans

This is a "connection" page, showing publications GEORGE JACKSON has written about Humans.
Connection Strength

0.434
  1. When is caring sharing? Primary care provider interdependence and continuity of care. JAAPA. 2023 Jan 01; 36(1):32-40.
    View in: PubMed
    Score: 0.023
  2. Teaming up in primary care: Membership boundaries, interdependence, and coordination. JAAPA. 2022 Feb 01; 35(2):1-10.
    View in: PubMed
    Score: 0.022
  3. Implementation science: Helping healthcare systems improve. JAAPA. 2020 01; 33(1):51-53.
    View in: PubMed
    Score: 0.019
  4. Primary care provider type: Are there differences in patients' intermediate diabetes outcomes? JAAPA. 2019 Jun; 32(6):36-42.
    View in: PubMed
    Score: 0.018
  5. Feasibility study: Effect of hand resistance exercise on handwriting in Parkinson's disease and essential tremor. J Hand Ther. 2018 Jan - Mar; 31(1):29-34.
    View in: PubMed
    Score: 0.015
  6. Implementation of Lung Cancer Screening in the Veterans Health Administration. JAMA Intern Med. 2017 03 01; 177(3):399-406.
    View in: PubMed
    Score: 0.015
  7. Patient characteristics associated with primary care PA and APRN roles. JAAPA. 2016 Dec; 29(12):1-6.
    View in: PubMed
    Score: 0.015
  8. Open-label randomized trial of titrated disease management for patients with hypertension: Study design and baseline sample characteristics. Contemp Clin Trials. 2016 09; 50:5-15.
    View in: PubMed
    Score: 0.015
  9. Multidirectional walk test in individuals with Parkinson's disease: a validity study. Int J Rehabil Res. 2015 Mar; 38(1):88-91.
    View in: PubMed
    Score: 0.013
  10. Hemichorea in a patient with diabetic ketoacidosis. J Neurol Sci. 2014 Jul 15; 342(1-2):189-91.
    View in: PubMed
    Score: 0.013
  11. Evidence for autophagic gridlock in aging and neurodegeneration. Transl Res. 2014 Jul; 164(1):1-12.
    View in: PubMed
    Score: 0.012
  12. Interactions between Tau and a-synuclein augment neurotoxicity in a Drosophila model of Parkinson's disease. Hum Mol Genet. 2014 Jun 01; 23(11):3008-23.
    View in: PubMed
    Score: 0.012
  13. TDP-43 Phosphorylation by casein kinase Ie promotes oligomerization and enhances toxicity in vivo. Hum Mol Genet. 2014 Feb 15; 23(4):1025-35.
    View in: PubMed
    Score: 0.012
  14. The downward spiral of tau and autolysosomes: a new hypothesis in neurodegeneration. Autophagy. 2012 Jul 01; 8(7):1144-5.
    View in: PubMed
    Score: 0.011
  15. Inner retinal visual dysfunction is a sensitive marker of non-proliferative diabetic retinopathy. Br J Ophthalmol. 2012 May; 96(5):699-703.
    View in: PubMed
    Score: 0.011
  16. Functional genomic screen and network analysis reveal novel modifiers of tauopathy dissociated from tau phosphorylation. Hum Mol Genet. 2011 Dec 15; 20(24):4947-77.
    View in: PubMed
    Score: 0.011
  17. Demise of the flies: why Drosophila models still matter. Prog Mol Biol Transl Sci. 2011; 100:483-98.
    View in: PubMed
    Score: 0.010
  18. Neurodegenerative models in Drosophila: polyglutamine disorders, Parkinson disease, and amyotrophic lateral sclerosis. Neurobiol Dis. 2010 Oct; 40(1):29-39.
    View in: PubMed
    Score: 0.010
  19. Emerging subspecialties in neurology: translational research in movement disorders. Neurology. 2009 Aug 25; 73(8):e40-1.
    View in: PubMed
    Score: 0.009
  20. Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders. Curr Opin Immunol. 2009 Jun; 21(3):359-63.
    View in: PubMed
    Score: 0.009
  21. Dissociation of tau toxicity and phosphorylation: role of GSK-3beta, MARK and Cdk5 in a Drosophila model. Hum Mol Genet. 2009 Jan 01; 18(1):164-77.
    View in: PubMed
    Score: 0.009
  22. A Drosophila model of ALS: human ALS-associated mutation in VAP33A suggests a dominant negative mechanism. PLoS One. 2008 Jun 04; 3(6):e2334.
    View in: PubMed
    Score: 0.008
  23. Guide to understanding Drosophila models of neurodegenerative diseases. PLoS Biol. 2008 Feb; 6(2):e53.
    View in: PubMed
    Score: 0.008
  24. A Drosophila model of mutant human parkin-induced toxicity demonstrates selective loss of dopaminergic neurons and dependence on cellular dopamine. J Neurosci. 2007 Jan 31; 27(5):981-92.
    View in: PubMed
    Score: 0.008
  25. A genomic screen for modifiers of tauopathy identifies puromycin-sensitive aminopeptidase as an inhibitor of tau-induced neurodegeneration. Neuron. 2006 Sep 07; 51(5):549-60.
    View in: PubMed
    Score: 0.007
  26. Drosophila models of neurodegenerative disease. NeuroRx. 2005 Jul; 2(3):438-46.
    View in: PubMed
    Score: 0.007
  27. Inactivation of Drosophila Apaf-1 related killer suppresses formation of polyglutamine aggregates and blocks polyglutamine pathogenesis. Hum Mol Genet. 2005 Feb 01; 14(3):357-72.
    View in: PubMed
    Score: 0.007
  28. A cluster-randomized trial of two implementation strategies to deliver audit and feedback in the EQUIPPED medication safety program. Acad Emerg Med. 2023 04; 30(4):340-348.
    View in: PubMed
    Score: 0.006
  29. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron. 2002 May 16; 34(4):509-19.
    View in: PubMed
    Score: 0.005
  30. Treatment Patterns in Essential Tremor: A Retrospective Analysis. Tremor Other Hyperkinet Mov (N Y). 2022; 12:10.
    View in: PubMed
    Score: 0.005
  31. Why the science of healthcare delivery matters to practicing PAs. JAAPA. 2020 Mar; 33(3):51-53.
    View in: PubMed
    Score: 0.005
  32. Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer's disease from a ferroptosis perspective. Prog Neurobiol. 2020 01; 184:101716.
    View in: PubMed
    Score: 0.005
  33. Uncoupling neuronal death and dysfunction in Drosophila models of neurodegenerative disease. Acta Neuropathol Commun. 2016 06 23; 4(1):62.
    View in: PubMed
    Score: 0.004
  34. Colorectal Cancer Statistics From the Veterans Affairs Central Cancer Registry. Clin Colorectal Cancer. 2016 12; 15(4):e199-e204.
    View in: PubMed
    Score: 0.004
  35. Impact of Clinical Pharmacy Specialists on the Design and Implementation of a Quality Improvement Initiative to Decrease Inappropriate Medications in a Veterans Affairs Emergency Department. J Manag Care Spec Pharm. 2016 Jan; 22(1):74-80.
    View in: PubMed
    Score: 0.004
  36. Treadmill exercise tests in persons with Parkinson's disease: responses and disease severity. Aging Clin Exp Res. 2016 Oct; 28(5):1009-14.
    View in: PubMed
    Score: 0.004
  37. Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies. Biol Psychiatry. 2015 Nov 15; 78(10):672-83.
    View in: PubMed
    Score: 0.003
  38. Collaborating across the Departments of Veterans Affairs and Defense to integrate mental health and chaplaincy services. J Gen Intern Med. 2014 Dec; 29 Suppl 4:885-94.
    View in: PubMed
    Score: 0.003
  39. Amyloid-? oligomers as a template for secondary amyloidosis in Alzheimer's disease. Neurobiol Dis. 2014 Nov; 71:14-23.
    View in: PubMed
    Score: 0.003
  40. The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes. Acta Neuropathol Commun. 2014 May 29; 2:56.
    View in: PubMed
    Score: 0.003
  41. Patient-reported quality of supportive care among patients with colorectal cancer in the Veterans Affairs Health Care System. J Clin Oncol. 2014 Mar 10; 32(8):809-15.
    View in: PubMed
    Score: 0.003
  42. Disruption of glycerol metabolism by RNAi targeting of genes encoding glycerol kinase results in a range of phenotype severity in Drosophila. PLoS One. 2013; 8(9):e71664.
    View in: PubMed
    Score: 0.003
  43. An examination of racial differences in process and outcome of colorectal cancer care quality among users of the veterans affairs health care system. Clin Colorectal Cancer. 2013 Dec; 12(4):255-60.
    View in: PubMed
    Score: 0.003
  44. Rapid accumulation of endogenous tau oligomers in a rat model of traumatic brain injury: possible link between traumatic brain injury and sporadic tauopathies. J Biol Chem. 2013 Jun 07; 288(23):17042-17050.
    View in: PubMed
    Score: 0.003
  45. Chaplaincy and mental health in the department of Veterans affairs and department of defense. J Health Care Chaplain. 2013; 19(1):3-21.
    View in: PubMed
    Score: 0.003
  46. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep. 2012; 2:700.
    View in: PubMed
    Score: 0.003
  47. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012 Apr; 8(4):445-544.
    View in: PubMed
    Score: 0.003
  48. Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J. 2012 May; 26(5):1946-59.
    View in: PubMed
    Score: 0.003
  49. Formation of immunoglobulin light chain amyloid oligomers in primary cutaneous nodular amyloidosis. Br J Dermatol. 2011 Dec; 165(6):1349-54.
    View in: PubMed
    Score: 0.003
  50. Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies. Curr Alzheimer Res. 2011 Sep; 8(6):659-65.
    View in: PubMed
    Score: 0.003
  51. Role of oligomers in the amyloidogenesis of primary cutaneous amyloidosis. J Am Acad Dermatol. 2011 Nov; 65(5):1023-31.
    View in: PubMed
    Score: 0.003
  52. Pathogenic VCP/TER94 alleles are dominant actives and contribute to neurodegeneration by altering cellular ATP level in a Drosophila IBMPFD model. PLoS Genet. 2011 Feb 03; 7(2):e1001288.
    View in: PubMed
    Score: 0.003
  53. Preparation and characterization of neurotoxic tau oligomers. Biochemistry. 2010 Nov 30; 49(47):10039-41.
    View in: PubMed
    Score: 0.002
  54. Therapeutic removal of amyloid deposits in cutaneous amyloidosis by localised intra-lesional injections of anti-amyloid antibodies. Exp Dermatol. 2010 Oct; 19(10):904-11.
    View in: PubMed
    Score: 0.002
  55. Inhaled insulin forms toxic pulmonary amyloid aggregates. Endocrinology. 2010 Oct; 151(10):4717-24.
    View in: PubMed
    Score: 0.002
  56. New vaccine development for chronic brain disease. Neuropsychopharmacology. 2010 Jan; 35(1):354.
    View in: PubMed
    Score: 0.002
  57. Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein. J Neurosci. 2009 Feb 18; 29(7):1962-76.
    View in: PubMed
    Score: 0.002
  58. Association of GSK3B with Alzheimer disease and frontotemporal dementia. Arch Neurol. 2008 Oct; 65(10):1368-74.
    View in: PubMed
    Score: 0.002
  59. Degradation of tau protein by puromycin-sensitive aminopeptidase in vitro. Biochemistry. 2006 Dec 19; 45(50):15111-9.
    View in: PubMed
    Score: 0.002
  60. Normal-repeat-length polyglutamine peptides accelerate aggregation nucleation and cytotoxicity of expanded polyglutamine proteins. Proc Natl Acad Sci U S A. 2006 Sep 26; 103(39):14367-72.
    View in: PubMed
    Score: 0.002
  61. Hydrolethalus syndrome is caused by a missense mutation in a novel gene HYLS1. Hum Mol Genet. 2005 Jun 01; 14(11):1475-88.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.